The clinical phase II study on the ophthalmic solution UF-021 ) for retinitis pigmentosa, a refractory disease, therapy for which there is currently no suitable drug, for the purpose of investigation of the possibility of improving the visual function in the central part of the fundus is performed. The patients who participated in the study Retinitis pigmentosa, which had advanced to the middle to late stage: a visual acuity of 0.5 or more, even with a narrow field of view. The study was conducted at six institutions in Japan conducted .
When retinitis pigmentosa progresses, patients suffer progressive night blindness, where it becomes difficult in low light, or visual field constriction and then deterioration of vision. In the final stage, they may be suffering severe vision loss or even blindness. It is used as a permanent disease and appropriate therapeutic drugs or therapeutic methods described are not currently established. Of of Research Study Group Regarding retinochoroidal and optic atrophy, a certain treatment of diseases research program of the Ministry of Health, Labour and Welfare in 2005, retinitis pigmentosa is the third cause of visual impairment and especially patients aged 60 or under, it is the leading cause of impaired vision.. Hereafter, the company intends to provide information on scientific ,, About retinitis Pigmentosaretinitis pigmentosa is an inherited disease and its prevalence is approximately 1 in 5,000 people in his world, and 1 in 4.Analysis showed, though the ACH – as are currently designed to and inserted – slightly delays the occurrence of the blast wave, it do not essential reducing the of the wavelength affect the brain tissue. After researchers You just added a conceptional facemask in said third simulation of the models showed significantly reduced in order out of stress in the brain, because the shield direct transfer compression waves to hindered face.